AGNG vs XLV

Key Takeaways

• AGNG offers targeted thematic exposure to the global aging population trend with 91% in health care and 9% in real estate (senior living), while XLV provides broad, large-cap U.S. health care sector coverage.
• XLV boasts superior cost efficiency at 0.08% expense ratio versus AGNG's 0.50%, alongside vastly higher liquidity and AUM exceeding $36 billion.
• Both exhibit defensive risk profiles with low beta to broader markets (AGNG beta 0.61 to S&P 500; XLV around 0.58), but XLV demonstrates lower short-term volatility due to its mega-cap concentration.
• AGNG holds 84 diversified global stocks with top holdings capped around 3-4%; XLV has 60 concentrated U.S. names, top 10 comprising nearly 60% of assets.
• Recent market cycles highlight health care's resilience amid sector rotations, with AGNG showing relative outperformance in one-year returns driven by longevity-focused holdings.
• Structural differences position AGNG for demographic tailwinds and XLV for stable S&P 500 health care benchmarking.

Introduction

Comparing the Global X Aging Population ETF (AGNG) and State Street Health Care Select Sector SPDR ETF (XLV) reveals complementary strategies within the resilient health care space. AGNG targets companies benefiting from the global aging demographic shift, offering thematic exposure to longevity and senior care. In contrast, XLV delivers broad, passive tracking of the S&P 500's health care constituents, emphasizing large-cap stability. These ETFs appeal to investors seeking defensive sector exposure amid macroeconomic uncertainty, interest rate fluctuations, and sector rotation toward non-cyclicals. While not direct competitors, they provide alternative pathways to health care growth—AGNG via niche innovation and XLV through established market leaders—making the comparison timely as capital flows favor defensive assets in recent market cycles.

Global X Aging Population ETF (AGNG) Overview

The Global X Aging Population ETF (AGNG), issued by Global X Management Company LLC, is a passive, thematic ETF launched in 2016 that tracks the Indxx Aging Population Thematic Index. It invests in companies worldwide deriving significant revenue from products and services supporting extended lifespans and senior quality of life, such as biotechnology, pharmaceuticals, medical devices, and senior living facilities.

AGNG holds 84 securities, promoting diversification with modified market-cap weighting: individual caps at 3% and floors at 0.3%, plus 60% industry limits. Top holdings include Novo Nordisk (3.82%), Welltower (3.23%), Ventas (3.19%), Edwards Lifesciences (3.14%), and Roche (3.12%). Sector allocations stand at 91.1% health care and 8.9% real estate. The expense ratio is 0.50%, with AUM around $81 million. The index rebalances annually. Liquidity features a 30-day median bid-ask spread of 0.36%, suitable for thematic investors.

State Street Health Care Select Sector SPDR ETF (XLV) Overview

The State Street Health Care Select Sector SPDR ETF (XLV), managed by State Street Global Advisors since 1998, passively replicates the Health Care Select Sector Index, representing the health care portion of the S&P 500. It spans pharmaceuticals, providers, biotech, equipment, and related sub-industries for comprehensive U.S. large-cap exposure.

XLV comprises 60 holdings, market-cap weighted with heavy concentration: top 10 account for about 59%. Leading positions are Eli Lilly (14.81%), Johnson & Johnson (10.31%), AbbVie (6.93%), UnitedHealth (6.73%), and Merck (5.34%). Allocations break down as pharmaceuticals (36.6%), providers/services (19.4%), biotech (18.4%), equipment/supplies (16.7%), and life sciences tools (8.6%). The low expense ratio of 0.08% supports its $36.6 billion AUM. It aligns with S&P quarterly rebalancing. Exceptional liquidity shines with a 0.01% 30-day median bid-ask spread and high daily volume.

Industry and Thematic Backdrop

The health care sector thrives amid a global aging crisis, with adults 65+ projected to reach 1.7 billion by 2053, driving demand for chronic care, biotech, and senior facilities. In the U.S., seniors represent 17% of the population but 37% of spending, with 70% needing long-term care. Macro catalysts include rising medical inflation (9-10%), Medicare expansions, drug pricing reforms, and AI-driven innovations like GLP-1 therapies and oncology advances.

Capital flows favor defensives as sector rotation persists amid geopolitical tensions and policy shifts. Regulatory scrutiny on pricing and patents poses risks, yet biotech M&A surges—over $300 billion in looming patent cliffs spur big pharma acquisitions. Workforce shortages exacerbate costs, but demographic inevitability bolsters resilience versus cyclicals.

Performance and Positioning Comparison

In recent weeks and months, both AGNG and XLV have navigated health care's relative stability amid broader drawdowns, with YTD declines milder than market averages. AGNG's one-year return around 14% outpaces XLV's 9%, fueled by global longevity holdings like Novo Nordisk and senior REITs amid earnings beats in biotech and real estate.

XLV's mega-cap tilt yields steadier volatility (4-5% monthly vs. AGNG's 5%), anchored by LLY and JNJ amid GLP-1 momentum. Over recent cycles, XLV edges in low-beta defense (0.58), while AGNG captures thematic upside from demographic shifts. Positioning reflects interest rate sensitivity—lower rates favor growth-oriented AGNG—and sector momentum, with both benefiting from defensive rotations but XLV from superior liquidity during volatility spikes.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes. Explore it today to uncover hidden gems in sectors like health care.

Tickeron AI Verdict

Tickeron’s AI currently favors XLV with moderate conviction (65-70% probability edge over 6-12 months). Its structural advantages—ultralow 0.08% costs, massive scale for liquidity, and concentrated large-cap diversification—outweigh AGNG's thematic appeal amid stable sector momentum. XLV's lower volatility and S&P benchmarking provide consistent trend capture, though AGNG merits allocation for aging-tailwind conviction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations